



Medicaid Pharmacy News

Dear Providers:

December 14, 2017

PREFERRED DRUG LIST (PDL) CHANGES (Effective 01/01/2018)

Please refer to www.wymedicaid.org for the complete PDL.

THERAPEUTIC CATEGORY	PREFERRED DRUG LIST CHANGES
ALLERGY/ASTHMA Inhaled Combination Agents	*Bevespi, Combivent, Dulera, fluticasone/salmeterol 232-14mcg, fluticasone/salmeterol 113-14mcg, fluticasone/salmeterol 55-14mcg, Trelegy, and Utibron will be non-preferred
ALLERGY/ASTHMA Steroid Inhalants	Pulmicort 0.25mg, 0.5mg, and 1mg suspension will be preferred *Generic budesonide 0.25mg, 0.5mg, and 1mg will be non-preferred
CROHN'S	*Stelara will be non-preferred
DERMATOLOGY Benzoyl Peroxide/Clindamycin Combos	*Onexton will be non-preferred
DERMATOLOGY Plaque Psoriasis – Step 2 Agent	Tremfya will be a Step 2 preferred agent and will require a diagnosis of Plaque Psoriasis, as well as a 56-day trial and failure of Enbrel
DIABETES SGLT2 Inhibitors	Farxiga will be preferred
GASTROINTESTINAL Mesalamine	Lialda will be preferred *Sfrowasa will be non-preferred
GOUT Colchicine	Colchicine will be preferred *Mitigare will be non-preferred
HEMATOLOGY Factor XA Inhibitor	Bevyxxa will be preferred with the required diagnosis
HEMATOLOGY Antihemophilic Factor VIII	Advate, Adynovate, Afstyla, Eloctate, Helixate FS, Hemofilm, Koate, Koate-DVI, Kogenate FS, Kogenate Bio-set, Kovaltry, Monoclate-P, Nuwiq, Obizur, Recombinate, Xyntha, and Xyntha Solofuse will be preferred *Novoeight will be non-preferred
HEMATOLOGY Antihemophilic Factor/VWF	Alphanate, Humate-P, and Wilate will be preferred

THERAPEUTIC CATEGORY	PREFERRED DRUG LIST CHANGES
HEPATITIS C Direct Acting Antivirals	Epclusa, Harvoni, Mavyret, and Vosevi will be preferred *Daklinza, Olysio, Sovaldi, Technivie, Viekira Pak, and Zepatier will be non-preferred
HYPERTENSION Angiotensin Receptor Blockers (ARB's)	Edarbi, olmesartan, and telmisartan will be preferred
HYPERTENSION ARB's/Diuretic Combos	Edarbyclor HCTZ, olmesartan HCTZ, and valsartan HCTZ will be preferred
INFECTIOUS DISEASE Anti-Retrovirals	Norvir solution will be preferred
MENTAL HEALTH Serotonin/Norepinephrine Reuptake Inhibitors (SNRI's)	*Generic desvenlafaxine will now be non-preferred (Brand name Pristiq will no longer be approved without a Brand Name Prior Authorization Request)
MENTAL HEALTH Atypical Antipsychotics	*Generic quetiapine XR will now be non-preferred (Brand name Seroquel XR will no longer be approved without a Brand Name Prior Authorization Request)
MENTAL HEALTH Long Acting Amphetamines	Generic amphetamine salts combo XR and dextroamphetamine CR capsules will now be preferred over the Brand name Adderall XR and Dexedrine CR
MENTAL HEALTH Selective Norepinephrine Reuptake Inhibitor	Generic atomoxetine will now be preferred over the Brand name Strattera
MULTIPLE SCLEROSIS	*Aubagio will now be non-preferred
OPHTHALMICS Anti-allergics	Pazeo will now be preferred *olopatadine 0.1% and 0.2% will be non-preferred
OPHTHALMICS Anti-inflammatory	*Durezol will now be non-preferred
OPHTHALMICS Dry Eye Agents	*Restasis Multidose and Xiidra will now be non-preferred
OPHTHALMICS Sympathomimetics	Alphagan P 0.1% will now be preferred
OVERACTIVE BLADDER	*Vesicare will now be non-preferred
PHOSPHATE BINDERS	*Phoslyra and lanthanum will now be non-preferred

ADDITIONAL THERAPEUTIC CRITERIA CHART (ATCC)

CHANGES (Effective 01/01/2018)

- Austedo will now be approved for the diagnosis of Tardive Dyskinesia
- Benlysta will be approved for the diagnosis of active, antibody-positive, systemic lupus erythematosus
- Cinryze and Haegarda will be approved for routine prophylaxis to prevent Hereditary Angioedema attacks in adolescents and adults
- Imbruvica will be approved for a diagnosis of cancer or chronic Graft vs. Host disease after failure of one or more lines of systemic therapy
- Praluent and Repatha will be approved for a diagnosis of homozygous familial hypercholesterolemia, have a diagnosis of heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease AND not at goal with a maximum dose statin, or be intolerant to statin therapy